This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-31 and is reviewed periodically as new material appears.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
=== Historical legality and modern-day usage in the United States === On October 24, 1968, possession of LSD was made illegal in the United States. The last FDA approved study of LSD in patients ended in 1980, while a study in healthy volunteers was made in the late 1980s. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993. As of 2017, about 10% of people in the United States have used LSD at some point in their lives, while 0.7% have used it in the last year. The use of LSD among US adults increased by 56.4% from 2015 to 2018. In November 2020, Oregon became the first US state to decriminalize possession of small amounts of LSD after voters approved Ballot Measure 110.
Additionally, with the increased sophistication of technology, trial-and-error approaches are often costly and difficult, as it may be difficult to account for all relevant dependencies among variables in a complex system. Molecular engineering efforts may include computational tools, experimental methods, or a combination of both.
== History == Fluvoxamine was developed by Kali-Duphar, part of Solvay Pharmaceuticals, Belgium, now Abbott Laboratories, and introduced as Floxyfral in Switzerland in 1983. It was approved by the U.S. Food and Drug Administration (FDA) in 1994, and introduced as Luvox in the US. In India, it is available, among several other brands, as Uvox by Abbott. It was one of the first SSRI antidepressants to be launched, and is prescribed in many countries to patients with major depression. It was the first SSRI, a non-TCA drug, approved by the U.S. FDA specifically for the treatment of OCD. At the end of 1995, more than ten million patients worldwide had been treated with fluvoxamine. Fluvoxamine was the first SSRI to be registered for the treatment of obsessive compulsive disorder in children by the FDA in 1997. In Japan, fluvoxamine was the first SSRI to be approved for the treatment of depression in 1999 and was later in 2005 the first drug to be approved for the treatment of social anxiety disorder. Fluvoxamine was the first SSRI approved for clinical use in the United Kingdom. Manufacturers include BayPharma, Synthon, and Teva, among others.
Because prokaryotic mRNA does not need to be processed or transported, translation by the ribosome can begin immediately after the end of transcription. Therefore, it can be said that prokaryotic translation is coupled to transcription and occurs co-transcriptionally. In eukaryotic cells the process of translation starts with the information stored in the nucleotide sequence of DNA. This is first transformed into mRNA, then transfer RNA (tRNA) specifies which three-nucleotide codon from the genetic code corresponds to which amino acid. Eukaryotic mRNA that has been processed and transported to the cytoplasm (i.e., mature mRNA) can then be translated by ribosomes. Translation may occur at ribosomes free in the cytoplasm, or targeted to the endoplasmic reticulum by the signal recognition particle. Therefore, unlike in prokaryotes, eukaryotic translation is not directly coupled to transcription. In some contexts, protein abundance can increase even when mRNA abundance decreases, because translation efficiency and protein turnover are regulated independently of transcript levels; this has been reported for mRNA and protein levels of EEF1A1 in breast cancer.
=== Newsweek's America's Best High Schools === In June 2010, seven PGCPS high school were listed in Newsweek's annual list of the top 1600 high schools in the nation. This was up from five county high schools which made the list from the previous year. The 2010 list included Eleanor Roosevelt High School in Greenbelt (#409), Oxon Hill High School in Oxon Hill (#957), Bowie High School in Bowie (#1,173), Laurel High School in Laurel (#1,343), High Point High School in Beltsville (#1,361), Central High School in Capitol Heights (#1,429), and Parkdale High School in Riverdale (#1,481). The schools are ranked on the number of Advanced Placement, International Baccalaureate and/or Cambridge tests taken by all students in a school in 2009, divided by the number of graduating seniors, called the "Challenge Index". The schools represent the top six percent of all public high schools in America. In June 2009, five PGCPS high schools were named in the best high schools list. It included Bowie High School in Bowie, Charles Herbert Flowers High School in Springdale, High Point High School in Beltsville, Oxon Hill High School in Oxon Hill, and Eleanor Roosevelt High School in Greenbelt. Eleanor Roosevelt ranked the highest out of county schools at 372nd on the nationwide list, Oxon Hill ranked 918th, High Point ranked 961st, Bowie ranked 1,370th, and Charles Herbert Flowers ranked 1,445th.
Sources: en.wikipedia.org
== External links == "Anatomy photo:39:01-0100". SUNY Downstate Medical Center. Archived from the original on March 5, 2016. jejunumileum at The Anatomy Lesson by Wesley Norman (Georgetown University) McGill (Wayback Machine copy)
The Mojave rattlesnake (Crotalus scutulatus), also called Mojave green, is another species which is considered to be dangerous. Although they have a reputation for being aggressive towards people, such behavior is not described in the scientific literature. Like other rattlesnakes, they will defend themselves vigorously when disturbed. The IP LD50 value is 0.18 mg/kg with an average venom yield between 50 and 150 mg per bite. The most common subspecies of Mojave rattlesnake (type A) has venom that is considered to be one of the most debilitating and potentially deadly of all North American snakes, although chances for survival are very good if medical attention is sought as soon as possible after a bite. Based on median LD50 values in lab mice, venom A from subspecies A Mojave rattlesnakes is more than ten times as toxic as venom B, from type B Mohave green rattlesnakes which lacks Mojave toxin. Medical treatment as soon as possible after a bite is critical to a positive outcome, dramatically increasing chances for survival. However, venom B causes pronounced proteolytic and hemorrhagic effects, similar to the bites of other rattlesnake species; these effects are significantly reduced or absent from bites by venom A snakes. Risk to life and limb is still significant, as with all rattlesnakes, if not treated as soon as possible after a bite. All rattlesnake venoms are complex cocktails of enzymes and other proteins that vary greatly in composition and effects, not only between species, but also between geographic populations within the same species.
A member of the People's Assembly (Arabic: عضو مجلس الشعب) refers to members of the Parliament of Syria. Historically, members of the Syrian parliament have been referred to in Arabic as nā'ib (نائب, "deputy"), plural nuwāb (نواب), a usage rooted in the legislature's earlier incarnation as the Chamber of Deputies (1932–1963). Following the parliament's reconstitution as the People's Assembly under Ba'athist rule in 1971, members came to be more commonly styled "member of the People's Assembly" in official and state-media usage. Nonetheless, "deputy" has persisted as a recognised designation, including in coverage of the current transitional-era Assembly formed after 2024.
Tanabe Young Investigator Award from the American College of Clinical Pharmacology (2014) Division for Drug Metabolism Early Career Achievement Award by the American Society for Pharmacology and Experimental Therapeutics (ASPET) (2015) The International Society for the Study of Xenobiotics (ISSX) North American New Investigator Award in Honor of James R. Gillette (2017) The Daily Record Leading Women Award (2017) Leon I. Goldberg Young Investigator Award from the American Society for Clinical Pharmacology and Therapeutics (2017) John J. Abel Award in Pharmacology from ASPET (2019)
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.